ADVFN - Advanced Financial Network.
HOME» NASDAQ » M » MNKD Stock Price » MNKD Stock News

Mannkind Share News

 Mannkind (mm) Stock Price
MNKD Stock Price
 Mannkind (mm) Stock Chart
MNKD Stock Chart
 Mannkind (mm) Stock News
MNKD Stock News
 Mannkind (mm) Company Information
MNKD Company Information
 Mannkind (mm) Stock Trades
MNKD Stock Trades

MannKind Says FDA Review Of Afrezza To Take Four More Weeks

DOW JONES NEWSWIRES MannKind Corp. (MNKD) said the U.S. Food and Drug Administration's review of its new drug application for its inhaled-insulin product for diabetics will require four additional weeks. The biopharmaceutical company, which has no products on the market currently, had been expecting FDA approval of Afrezza by Wednesday. MannKind has been hoping to succeed where larger drug makers have failed. In the mid-2000s, several companies were seeking to bring an inhaled formulation of insulin to market as an alternative to injections. The FDA initially had sought more information from MannKind in March about how the available data support the clinical utility of Afrezza in the marketplace, though the company at the time still planned a 2011 launch of the product. The FDA accepted its resubmission in July. The company also was dealt a setback in November when a former senior manager accused the drug developer of unlawful practices in its conduct of clinical trials, an accusation the company denies. Shares closed Monday at $7.97 and were inactive premarket. The stock is still down 9% this year, though it has recovered some of its losses since the FDA's action in March. -By Tess Stynes, Dow Jones Newswires; 212-416-2481; Tess.Stynes@dowjones.com

Stock News for Mannkind (MNKD)
DateTimeHeadline
06/30/201409:34:43U.S. Hot Stocks: Hot Stocks To Watch
04/07/201409:55:50U.S. Hot Stocks: Hot Stock to Watch
04/03/201409:30:06MARKET SNAPSHOT: U.S. Stocks Up; S&P 500 Hits Record
04/02/201412:16:22MARKET SNAPSHOT: U.S. Stocks Edge Higher; S&P 500 Hits Record
04/02/201409:27:32U.S. Hot Stock Futures: Hot Stocks to Watch
11/15/201308:55:36Highbridge Capital Management 3Q 13F: Holdings As -2-
11/15/201308:55:35Highbridge Capital Management 3Q 13F: Holdings As Of Sep 30
11/15/201308:53:19D. E. Shaw & Co. LP 3Q 13F: Largest Eliminations
11/15/201308:53:15D. E. Shaw & Co. LP 3Q 13F: Largest Purchases
11/15/201308:53:15D. E. Shaw & Co. LP 3Q 13F: Largest Sales
11/15/201308:53:15D. E. Shaw & Co. LP 3Q 13F: Largest Eliminations -2-
11/15/201306:39:13CR Intrinsic Investors 3Q 13F: Largest Purchases -2-
11/15/201306:39:13CR Intrinsic Investors 3Q 13F: Holdings As Of Sep 30
11/15/201306:39:13CR Intrinsic Investors 3Q 13F: Holdings As Of Sep -2-
11/15/201306:39:13CR Intrinsic Investors 3Q 13F: Largest Purchases
11/14/201307:19:32The Vanguard Group 3Q 13F: Largest Purchases
11/14/201307:19:32The Vanguard Group 3Q 13F: Largest Purchases -2-
08/12/201306:29:50U.S. HOT STOCK FUTURES: HOT STOCKS TO WATCH
06/24/201119:46:35Amylin, MannKind Shares Rise On Diabetes Data Releases
12/30/201017:22:24Approvals Of New Drugs Down In 2010 Vs 2009, 2008

Mannkind and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad